Clinical trials: Vascular Risk
Ischemic Stroke, Cognitive Impairment
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
The purpose of this study is to determine whether a non-invasive brain stimulation technique, transcranial direct current stimulation (tDCS), combined with traditional cognitive therapy will improve cognitive function in patients…
- Trial name
- TRAINS (NCT04897334)
- Testing
- tDCS, Cognitive Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Pennsylvania
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cardiovascular Diseases, Heart Diseases
Genetic Epidemiology of CHD Risk Factors in Blacks
To determine the genetic epidemiology of coronary heart disease (CHD) risk factors in Blacks.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Trial name
- NCT00005364
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 2
Immune Profile and Complication Risk in Type 2 Diabetes
The aim of this study is to investigate the relation between individual differences in pattern recognition molecules (PRM's) in the innate immune system and the prevalence and development of vascular complications in patients…
- Trial name
- IMPACT (NCT00674271)
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Coronary Artery Disease
Cardiovascular Systems Inc. (CSI) pVAD First in Human Study
This study will collect initial clinical data on the CSI pVAD system to inform device design and finalization.
- Trial name
- NCT05315544
- Testing
- CSI pVAD system
- Where
- Georgia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Devices
Aging, Alzheimer Disease
Tennessee Alzheimer's Project
The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals…
- Conditions
- Aging, Alzheimer Disease, Biomarker, Cognitive Dysfunction
- Trial name
- TAP (NCT05372172)
- Testing
- none, observational study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Venous Thrombosis
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event.
- Trial name
- TACT (NCT02892565)
- Testing
- Blood sample
- Volunteers
- 122 people
- Sponsor
- Central Hospital, Nancy, France
Ischemic Cerebral Infarction
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by…
- Trial name
- ORIS (NCT07242599)
- Testing
- High target group, Low target group
- Where
- 199 sites in China
- Volunteers
- 4,810 people
- Sponsor
- Beijing Tiantan Hospital
Atrial Fibrillation, Deep Vein Thrombosis
Association Between Genetic Variant Scores and Warfarin Effect
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
- Trial name
- AWARE1 (NCT03894878)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Cerebral Ischemia
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Safety and effect of SANGUINATE on patients DCI following SAH.
- Trial name
- NCT02323685
- Testing
- SANGUINATE™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Prolong Pharmaceuticals
Pulmonary Embolism
Nudging Provider Adoption of Clinical Decision Support: Implementation of an EHR-Agnostic Pulmonary Embolism Risk Prediction Tool
The purpose of this study is to examine the impact of the nudge implementation strategy (CDS tool + Nudge) on adoption of guideline-concordant CT ordering for pulmonary embolism (PE) in 10 EDs.
- Trial name
- NCT07249385
- Testing
- Clinical Decision Support (CDS) tool with Nudges
- Where
- 3 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Thromboembolism
Evaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments
Patients hospitalized in internal wards are at risk for VTE. The current guidelines recommend the use of thromboprophylaxis for 7-10 days among patients who are at increased risk for VTE.
- Trial name
- NCT03073915
- Volunteers
- 4,000 people
- Sponsor
- Hadassah Medical Organization
Peripheral Arterial Disease
Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD
Peripheral arterial disease (PAD), a disabling condition, affects 800,000 Canadians. People with PAD suffer from poor quality of life due to leg pain, which makes walking difficult. They also have a high risk of heart disease.
- Trial name
- HY-PAD (NCT03649204)
- Testing
- HY-PAD
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Diabetes Mellitus, Metabolic Syndrome
Effect of Bariatric Surgery "Digestive Adaptations III" on Cardiovascular Risk
Introduction- Primary prevention is the main strategy to control the global burden of cardiovascular disease. In clinical practice, food restriction represents a valuable preventive resource.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome, Obesity, Atherosclerosis
- Trial name
- ADIII (NCT01581099)
- Testing
- Digestive Adaptations III surgery
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Atrial Fibrillation, Stroke
Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry
This study is aimed to validate the existing stroke risk stratification model for patients with atrial fibrillation (AF) (CHA2DS2-VASc Score, CHADS2 Score, ATRIA score, ABC score, etc.) and establish a new stroke risk assessment…
- Trial name
- NCT05598632
- Where
- China
- Volunteers
- 22,000 people
- Sponsor
- China National Center for Cardiovascular Diseases
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Hypertension, Left Ventricular Hypertrophy
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH.
- Trial name
- NCT00139555
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Novartis
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Atrial Fibrillation
Pleotropic Effect of New Oral Anticoagulants
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel.
- Trial name
- NCT02544932
- Testing
- dabigatran, ribaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.